Innovus Pharmaceuticals Aktie [WKN DE: A1W5D3 / ISIN: US45778V1061]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Innovus Pharmaceuticals Inc

12.09.19		Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals (Businesswire)
13.08.19		Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter (Businesswire)
09.08.19		Innovus Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 13, 2019 (Businesswire)
22.07.19		Innovus Pharmaceuticals Announces that its Delta Prime Savings Club E-Commerce Marketplace is on Track for Annual Sales of Approximately $3 million in 2019 (Businesswire)
19.06.19		Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada (Businesswire)
06.06.19		Innovus Pharmaceuticals Receives Notification to Market and Sell CarvaNum® for Muscle Recovery in the European Union (Businesswire)
04.06.19		Innovus Pharma Expands its OTC Drug Pipeline with the Addition of OmepraCare™ (a Competitor of Prilosec® OTC) (Businesswire)
30.05.19		Innovus Pharma Releases Results from Annual Shareholders Meeting (Businesswire)
28.05.19		Following Its Recent Approval from Health Canada for the Relief of Neuropathy Pain, Innovus Pharma Announces Receipt of Notification to Commercialize Diabasens® in the European Union (Businesswire)
15.05.19		Innovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 Million, a 18.0% Increase from Comparable Quarter in the Prior Year (Businesswire)
13.05.19		Innovus Pharma’s Partner Lavasta Receives Approval from Algeria to Market and Sell Zestra® and Zestra Glide® in that Country (Businesswire)
08.05.19		Innovus Pharma Announces a Second Partnered United States OTC ANDA for Minoxidil 5% Foam for Men and Women (Businesswire)
06.05.19		Innovus Pharmaceuticals Reports Preliminary Q1 2019 Sales Revenue of Approximately $5.4 million (Businesswire)
18.04.19		Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare® (Businesswire)
04.04.19		Innovus Pharma Receives Expanded Claims for Its UriVarx® Product in Canada to Include Symptoms of Urinary Incontinence (Businesswire)
01.04.19		Innovus Pharma Reports Record Annual Revenue for Fiscal 2018 of $24.0 million in line with Previous Guidance and Product Gross Margins of 81% (Businesswire)
27.03.19		Innovus Pharmaceuticals to Release its Annual 2018 Financial Results on Monday, April 1, 2019 (Businesswire)
21.03.19		Innovus Pharmaceuticals Reports Preliminary Annual 2018 Net Revenue of $24 Million (Businesswire)
21.03.19		Innovus Pharmaceuticals Reports Preliminary Annual 2018 Net Revenue of $24 Million (Businesswire)
06.03.19		Innovus Pharma Announces the Launch of its Diabasens® Product in Canada (Businesswire)
01.03.19		Innovus Pharma Announces the Approval of its Diabasens® Product in Canada Indicated to Relieve Cutaneous Pain Associated with Diabetic Neuropathy (Businesswire)
28.02.19		Innovus Pharma Announces the Approval of its BH™ Testosterone Booster Product in Canada for the Indication to Help to Support Testosterone Levels and Production in Adult Males (Businesswire)
26.02.19		Innovus Pharma’s Subsidiary, Novalere, Inc., Announces Launch of Its First Hemp-Derived Cannabidiol Oil-Based Product, MZS Sleeping Aid™ in the United States (Businesswire)
21.02.19		Innovus Pharma Announces Regulatory Filings by its International Distribution Partner, Lavasta Pharma, for ProstaGorx® in Certain Gulf Countries (Businesswire)
01.02.19		Innovus Pharma’s Product FlutiCare® Ranks #2 Behind Flonase® in Amazon®’s Fluticasone Propionate and Allergy Nasal Spray Categories (Businesswire)
31.01.19		Innovus Pharma Announces the Approval and Launch of its OTC Hemorrhoid Xyralid® Suppositories in Canada (Businesswire)
31.12.18		Innovus Pharmaceuticals Announces $3.17 Million Private Placement (Businesswire)
14.12.18		Innovus Pharma Announces All Cash Acquisition of All of the Assets of SupplementHunt.com, an E-Commerce Store with its Proprietary Sales Platform and Marketing Technology (Businesswire)
10.12.18		Innovus Pharma Announces Initiation of a Clinical Study to Evaluate the Tolerance and the Effect of Musclin™ on Muscle Health in Adults in the United States (Businesswire)
19.11.18		Innovus Pharmaceuticals Acquires Worldwide Rights to Four Products from Boston Topicals, LLC (Businesswire)
14.11.18		Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 Million for the Third Quarter 2018 and $19.2 Million for the First Nine Months of 2018 (Businesswire)
08.11.18		Innovus Pharmaceuticals to Release Its Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 (Businesswire)
05.11.18		Innovus Pharmaceuticals Reports Preliminary Q3 2018 Sales Revenue of $7.0 million to $7.1 million (Businesswire)
23.10.18		Innovus Pharma Receives Approval for Medicare Reimbursement for its GlucoGorx™ Blood Glucose Monitoring System and GlucoGorx™ Blood Glucose Test Strip Products (Businesswire)
15.10.18		Innovus Pharma Receives Approval from Amazon® to Expand its Amazon® Stores to Japan (Businesswire)
29.08.18		Innovus Pharma to Present at H.C. Wainwright 20th Annual Global Investment Conference (Businesswire)
14.08.18		Innovus Pharma Reports New Quarterly Revenue Record of $7.3 million for the Second Quarter 2018 and Expands to Canadian Market (Businesswire)
07.08.18		Innovus Pharma Announces Three Regulatory Filings with Health Canada for Its Products: Xyralid® Suppositories, Beyond Human® Testosterone and RecalMax™ (Businesswire)
03.08.18		Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 (Businesswire)
19.07.18		Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic (Businesswire)
17.07.18		Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million (Businesswire)
21.06.18		Innovus Pharma Receives Approval from Amazon® to Expand its Amazon® Stores to Europe Covering the United Kingdom, France, Germany, Spain and Italy (Businesswire)
06.06.18		Innovus Pharma Announces the Launch of Its Product AllerVarx™ in Canada for Allergic Rhinitis (Businesswire)
04.06.18		Innovus Pharma Announces the Approval of Its Product ProstaGorx™ in Canada for Benign Prostatic Hyperplasia ("BPH”) (Businesswire)
31.05.18		Innovus Pharma Chief Executive Officer to Present at 8th Annual LD Micro Invitational Conference (Businesswire)
18.05.18		Innovus Pharma to Exhibit Its FlutiCare® and AllerVarx™ Products at the American Thoracic Society Event in San Diego from Sunday, May 20, 2018 to Tuesday, May 22, 2018 (Businesswire)
17.05.18		Innovus Pharma Announces the Launch of its Product Vesele® in Canada (Businesswire)
04.05.18		Innovus Pharmaceuticals to Release Its First Quarter 2018 Financial Results on Monday, May 14, 2018 (Businesswire)
26.04.18		Innovus Pharma Announces the Launch of its Hemorrhoid Drug Xyralid® in Canada (Businesswire)
23.04.18		Innovus Pharma Expands its Senior Management with the Addition of Ryan Selhorn, CPA, as its Vice President, Chief Financial Officer (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA-Aktie profitiert von starkem Plus bei Umsatz und Gewinn

SBO-Aktie rutscht deutlich ab: Schoeller-Bleckmann verzeichnet deutlichen Gewinneinbruch nach drei Quartalen

UNIQA steigert Ergebnis trotz Unwetterschäden - Trennung von Beteiligungen in Albanien, Kosovo und Nordmazedonien - Aktie profitiert

Neuer Rekord: Bitcoin klettert über 99.000 Dollar

Kryptorally setzt sich fort: Bitcoin, Dogecoin, Ethereum & Co. am Donnerstagmittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	24.11.2024 00:27
Kaufwert:	EUR
	Hinzufügen Speichern